Leucine-based motif and clostridial neurotoxins

    公开(公告)号:US07705124B2

    公开(公告)日:2010-04-27

    申请号:US12053998

    申请日:2008-03-24

    IPC分类号: C07K14/33

    摘要: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.

    Leucine-based motif and Clostridial neurotoxins
    12.
    发明授权
    Leucine-based motif and Clostridial neurotoxins 有权
    亮氨酸为主题和梭菌神经毒素

    公开(公告)号:US07393925B2

    公开(公告)日:2008-07-01

    申请号:US11039268

    申请日:2005-01-19

    IPC分类号: C07K14/33

    摘要: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.

    摘要翻译: 包含神经毒素的改性神经毒素包括结构修饰,其中所述结构修饰改变了修饰神经毒素相对于相同神经毒素的生物学持续性,优选生物半衰期而没有结构修饰。 结构修饰包括加入或缺失基于亮氨酸的基序或其部分。 在一个实施方案中,制备修饰的神经毒素的方法包括使用重组技术。 在另一个实施方案中,使用经修饰的神经毒素治疗生物学障碍的方法包括治疗自主神经障碍,神经肌肉疾病或疼痛。

    Leucine-based motif and clostridial neurotoxins
    13.
    发明授权
    Leucine-based motif and clostridial neurotoxins 有权
    基于亮氨酸的主题和梭菌神经毒素

    公开(公告)号:US07671177B2

    公开(公告)日:2010-03-02

    申请号:US12057642

    申请日:2008-03-28

    IPC分类号: C07K14/33

    摘要: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.

    摘要翻译: 包含神经毒素的改性神经毒素包括结构修饰,其中所述结构修饰改变了修饰神经毒素相对于相同神经毒素的生物学持续性,优选生物半衰期而没有结构修饰。 结构修饰包括加入或缺失基于亮氨酸的基序或其部分。 在一个实施方案中,制备修饰的神经毒素的方法包括使用重组技术。 在另一个实施方案中,使用经修饰的神经毒素治疗生物学障碍的方法包括治疗自主神经障碍,神经肌肉疾病或疼痛。

    LEUCINE-BASED MOTIF AND CLOSTRIDIAL NEUROTOXINS
    14.
    发明申请
    LEUCINE-BASED MOTIF AND CLOSTRIDIAL NEUROTOXINS 有权
    基于胆碱的动物和离体神经毒素

    公开(公告)号:US20090202591A1

    公开(公告)日:2009-08-13

    申请号:US12416470

    申请日:2009-04-01

    IPC分类号: A61K39/08 C07K14/33

    摘要: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.

    摘要翻译: 包含神经毒素的改性神经毒素包括结构修饰,其中所述结构修饰改变了相对于相同的神经毒素而没有结构修饰的生物学持久性,例如修饰的神经毒素的生物半衰期和/或生物活性。 在一个实施方案中,制备修饰的神经毒素的方法包括使用重组技术。 在另一个实施方案中,使用经修饰的神经毒素治疗病症的方法包括治疗各种疾病,神经肌肉营养和疼痛。

    Leucine-based motifs and enhanced biological persistence of clostridial neurotoxins
    15.
    发明授权
    Leucine-based motifs and enhanced biological persistence of clostridial neurotoxins 有权
    基于亮氨酸的图案和增强的梭菌神经毒素的生物持续性

    公开(公告)号:US07534863B2

    公开(公告)日:2009-05-19

    申请号:US10753537

    申请日:2004-01-08

    IPC分类号: C07K14/33

    摘要: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.

    摘要翻译: 包含神经毒素的改性神经毒素包括结构修饰,其中所述结构修饰改变了相对于相同的神经毒素而没有结构修饰的生物学持久性,例如修饰的神经毒素的生物半衰期和/或生物活性。 在一个实施方案中,制备修饰的神经毒素的方法包括使用重组技术。 在另一个实施方案中,使用经修饰的神经毒素治疗病症的方法包括治疗各种疾病,神经肌肉营养和疼痛。

    LEUCINE-BASED MOTIF AND CLOSTRIDIAL NEUROTOXINS

    公开(公告)号:US20080214781A1

    公开(公告)日:2008-09-04

    申请号:US12054667

    申请日:2008-03-25

    IPC分类号: C07K2/00

    摘要: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.

    LEUCINE-BASED MOTIF AND CLOSTRIDIAL NEUROTOXINS

    公开(公告)号:US20080177042A1

    公开(公告)日:2008-07-24

    申请号:US12057642

    申请日:2008-03-28

    IPC分类号: C07K14/33

    摘要: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.